Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

BACKGROUND: Transitioning patients from an originator to a corresponding biosimilar has been extensively studied in both randomized controlled trials and observational studies. Although transitioning is considered well-tolerated, with no negative impacts on efficacy and/or safety, 2.6–25.8% of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijboom, Rosanne W., Gardarsdottir, Helga, Egberts, Toine C. G., Giezen, Thijs J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847209/
https://www.ncbi.nlm.nih.gov/pubmed/34870802
http://dx.doi.org/10.1007/s40259-021-00508-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847209/
https://www.ncbi.nlm.nih.gov/pubmed/34870802
http://dx.doi.org/10.1007/s40259-021-00508-4

Ejemplares similares